Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Gyre Therapeutics (GYRE) Change in Intangibles (2022 - 2026)

Gyre Therapeutics has reported Change in Intangibles over the past 4 years, most recently at -$4000.0 for Q4 2025.

Quarterly Change in Intangibles fell 100.49% to -$4000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $733000.0 through Dec 2025, down 9.95% year-over-year, with the annual reading at $733000.0 for FY2025, 9.84% down from the prior year.
Change in Intangibles was -$4000.0 for Q4 2025 at Gyre Therapeutics, down from $15000.0 in the prior quarter.
Over five years, Change in Intangibles peaked at $810000.0 in Q4 2024 and troughed at -$55.0 million in Q4 2022.
The 4-year median for Change in Intangibles is $8500.0 (2023), against an average of -$5.3 million.
Year-over-year, Change in Intangibles surged 80900.0% in 2024 and then crashed 100.49% in 2025.
A 4-year view of Change in Intangibles shows it stood at -$55.0 million in 2022, then soared by 100.0% to $1000.0 in 2023, then surged by 80900.0% to $810000.0 in 2024, then crashed by 100.49% to -$4000.0 in 2025.
Per Business Quant, the three most recent readings for GYRE's Change in Intangibles are -$4000.0 (Q4 2025), $15000.0 (Q3 2025), and $23000.0 (Q2 2025).